DNA X, Inc. (SONM)
DNA X, Inc. (SONM)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Repayments of short-term borrowings | NaN | NaN | 0 | 591 |
| Proceeds from stock option exercises, net of taxes paid on vested restricted stock units | NaN | NaN | NaN | 0 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | -126 | 4,845 | 8,952 |
| Proceeds from promissory note, net of issuance costs | 0 | 1,260 | 2,320 | 2,790 |
| Proceeds (payments) from short-term borrowings | NaN | -555 | NaN | NaN |
| Proceeds from short-term borrowings | 0 | NaN | NaN | NaN |
| Net cash provided by financing activities | 0 | 1,170 | 7,165 | 11,151 |
| Depreciation and amortization | 0 | 1,496 | 952 | 1,852 |
| Loss on extinguishment of debt | NaN | -161 | NaN | NaN |
| Impairment of contract fulfillment assets | NaN | 984 | 0 | 1,084 |
| Release of customer allowance liability | 0 | -778 | 61 | -5,490 |
| Other | 0 | -243 | -79 | -36 |
| Non-trade receivable | 0 | 3,161 | 2,874 | -152 |
| Gain on sale of assets, net assets transferred | 15,563 | NaN | NaN | NaN |
| Amortization of debt discount and issuance costs | 43 | NaN | NaN | NaN |
| Loss on remeasurement of derivative liability | 227 | NaN | NaN | NaN |
| Investment income from dna x llc under the equity method | 48 | NaN | NaN | NaN |
| Accounts receivable | -250 | 1,813 | 628 | -1,330 |
| Inventory | -5,490 | 0 | -181 | 0 |
| Inventory | NaN | -3,831 | 968 | -986 |
| Prepaid expenses and other current assets | -1,663 | -1,303 | -1,400 | 589 |
| Contract fulfillment assets | NaN | 4,984 | 1,947 | 4,383 |
| Contract fulfilment assets | -129 | NaN | NaN | NaN |
| Other assets | 103 | 4 | -1 | 18 |
| Accounts payable | -2,653 | 11,971 | -175 | -2,265 |
| Accrued liabilities | -1,288 | -1,932 | 1,407 | -1,433 |
| Deferred tax assets | -1,364 | 1,377 | NaN | NaN |
| Deferred tax liabilities | 600 | NaN | NaN | NaN |
| Income tax payable | -221 | 784 | 64 | 51 |
| Stock-based compensation (211 from continuing and 93 from discontinued operations for 2026 and all from discontinued operations for 2025-see note 7) | 304 | 159 | 166 | 1,216 |
| Net loss | 6,340 | -8,887 | -4,753 | -7,017 |
| Net cash used in operating activities | -3,466 | -2,004 | -7,034 | -14,488 |
| Purchase of property and equipment | NaN | NaN | NaN | 0 |
| Net cash received from sale of assets | 3,358 | NaN | NaN | NaN |
| Net cash provided by investing activities | 3,358 | NaN | NaN | 0 |
| Net decrease in cash and cash equivalents | -108 | -834 | 131 | -3,337 |
| Cash and cash equivalents at beginning of period | 1,303 | 2,137 | 5,343 | NaN |
| Cash and cash equivalents at end of period | 1,195 | 1,303 | 2,137 | NaN |